SETD2 mutations have been reported at rates of 11.6% and 7.4% in TCGA and Memorial Sloan-Kettering Cancer Center cohorts, respectively [23], and Liu et al. [24] reported a rate of deficiency of SETD2 of 34.1% in a multicenter study. This evidence concerns the gene SETD2 and cancer.